Cargando…
Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)
BACKGROUND: Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized phase 2 study in patients with metastatic colorectal cancer. The Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy (POLAR)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678401/ https://www.ncbi.nlm.nih.gov/pubmed/36308441 http://dx.doi.org/10.1093/jncics/pkac075 |
_version_ | 1784833981464707072 |
---|---|
author | Pfeiffer, Per Lustberg, Maryam Näsström, Jacques Carlsson, Stefan Persson, Anders Nagahama, Fumiko Cavaletti, Guido Glimelius, Bengt Muro, Kei |
author_facet | Pfeiffer, Per Lustberg, Maryam Näsström, Jacques Carlsson, Stefan Persson, Anders Nagahama, Fumiko Cavaletti, Guido Glimelius, Bengt Muro, Kei |
author_sort | Pfeiffer, Per |
collection | PubMed |
description | BACKGROUND: Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized phase 2 study in patients with metastatic colorectal cancer. The Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy (POLAR) program aimed to assess efficacy and safety of CaM in the prevention of CIPN in patients treated with oxaliplatin in adjuvant (POLAR-A, ClinicalTrials.gov.NCT04034355) or metastatic (POLAR-M, ClinicalTrials.gov.NCT03654729) settings. METHODS: Two randomized, placebo-controlled phase 3 trials investigated patient-reported, moderate-to-severe CIPN 9 months after beginning folinic acid, 5-fluorouracil, and oxaliplatin therapy with or without CaM. In POLAR-A, patients with stage III or high-risk stage II colorectal cancer were randomly assigned 1:1 to receive CaM 5 μmol/kg or placebo. In POLAR-M, patients with metastatic colorectal cancer were randomly assigned 1:1:1 to receive CaM 5 μmol/kg, CaM 2 μmol/kg, or placebo. RESULTS: POLAR-A (n = 301) and POLAR-M (n = 291) were terminated early following unexpected hypersensitivity reactions in CaM-treated patients. In a combined analysis of month 9 CIPN (primary endpoint) data from both trials (CaM 5 μmol/kg, n = 175; placebo, n = 176), 54.3% of patients in the CaM group had moderate-to-severe CIPN compared with 40.3% in the placebo group. The estimated relative risk for moderate-to-severe CIPN at month 9 was 1.37 (95% confidence interval = 1.01 to 1.86; P = .045). A higher proportion of patients experienced serious hypersensitivity reactions across both trials with CaM treatment (3.6%) than with placebo (0.8%). CONCLUSION: The POLAR clinical studies failed to meet their primary endpoint. These results highlight the challenges of targeting oxidative stress for preventing CIPN in both the adjuvant and metastatic settings. |
format | Online Article Text |
id | pubmed-9678401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-96784012022-11-22 Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) Pfeiffer, Per Lustberg, Maryam Näsström, Jacques Carlsson, Stefan Persson, Anders Nagahama, Fumiko Cavaletti, Guido Glimelius, Bengt Muro, Kei JNCI Cancer Spectr Article BACKGROUND: Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized phase 2 study in patients with metastatic colorectal cancer. The Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy (POLAR) program aimed to assess efficacy and safety of CaM in the prevention of CIPN in patients treated with oxaliplatin in adjuvant (POLAR-A, ClinicalTrials.gov.NCT04034355) or metastatic (POLAR-M, ClinicalTrials.gov.NCT03654729) settings. METHODS: Two randomized, placebo-controlled phase 3 trials investigated patient-reported, moderate-to-severe CIPN 9 months after beginning folinic acid, 5-fluorouracil, and oxaliplatin therapy with or without CaM. In POLAR-A, patients with stage III or high-risk stage II colorectal cancer were randomly assigned 1:1 to receive CaM 5 μmol/kg or placebo. In POLAR-M, patients with metastatic colorectal cancer were randomly assigned 1:1:1 to receive CaM 5 μmol/kg, CaM 2 μmol/kg, or placebo. RESULTS: POLAR-A (n = 301) and POLAR-M (n = 291) were terminated early following unexpected hypersensitivity reactions in CaM-treated patients. In a combined analysis of month 9 CIPN (primary endpoint) data from both trials (CaM 5 μmol/kg, n = 175; placebo, n = 176), 54.3% of patients in the CaM group had moderate-to-severe CIPN compared with 40.3% in the placebo group. The estimated relative risk for moderate-to-severe CIPN at month 9 was 1.37 (95% confidence interval = 1.01 to 1.86; P = .045). A higher proportion of patients experienced serious hypersensitivity reactions across both trials with CaM treatment (3.6%) than with placebo (0.8%). CONCLUSION: The POLAR clinical studies failed to meet their primary endpoint. These results highlight the challenges of targeting oxidative stress for preventing CIPN in both the adjuvant and metastatic settings. Oxford University Press 2022-10-29 /pmc/articles/PMC9678401/ /pubmed/36308441 http://dx.doi.org/10.1093/jncics/pkac075 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Pfeiffer, Per Lustberg, Maryam Näsström, Jacques Carlsson, Stefan Persson, Anders Nagahama, Fumiko Cavaletti, Guido Glimelius, Bengt Muro, Kei Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) |
title | Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) |
title_full | Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) |
title_fullStr | Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) |
title_full_unstemmed | Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) |
title_short | Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) |
title_sort | calmangafodipir for prevention of oxaliplatin-induced peripheral neuropathy: two placebo-controlled, randomized phase 3 studies (polar-a/polar-m) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678401/ https://www.ncbi.nlm.nih.gov/pubmed/36308441 http://dx.doi.org/10.1093/jncics/pkac075 |
work_keys_str_mv | AT pfeifferper calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm AT lustbergmaryam calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm AT nasstromjacques calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm AT carlssonstefan calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm AT perssonanders calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm AT nagahamafumiko calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm AT cavalettiguido calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm AT glimeliusbengt calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm AT murokei calmangafodipirforpreventionofoxaliplatininducedperipheralneuropathytwoplacebocontrolledrandomizedphase3studiespolarapolarm |